Notable Upgrades: Cerner (CERN), Ritter Pharmaceuticals (RTTR), Bristol-Myers Squibb (BMY), Orbotech (ORBK)

Cerner Corporation (CERN) was reiterated an ‘Outperform’ by RBC Capital Markets analysts on Wednesday. The broker also raised its price target on the stock to $70 from $65.

In a report published Wednesday, Chardan Capital Markets analysts initiated coverage on Ritter Pharmaceuticals, Inc. (RTTR) with a ‘Buy’ rating and $3.00 price target.

RTTR has a high Wall Street target of $7.00. In the past 52 weeks, shares of Los Angeles, California-based company have traded between a low of $2 and a high of $5.50 and are now at $2.54.

Shares are up down 55.65% since the beginning of the year.

Analysts at Guggenheim are out with a report this morning upgrading shares of Bristol-Myers Squibb Company (BMY) with a ‘Buy’ from ‘Neutral’ rating.

Bristol-Myers Squibb Co. shares are currently priced at 64.96x this year’s forecasted earnings, Ticker has a forward P/E of 30.12 and t-12 price-to-sales ratio of 6.89. EPS for the same period is $1.06.

In the past 52 weeks, shares of New York-based company have traded between a low of $51.82 and a high of $70.54 and are now at $68.99. Shares are up 18.38% year-over-year and 17.69% year-to-date.

Orbotech Ltd. (ORBK) was reiterated as ‘Outperform’ with $35 from $24 price target on Wednesday by Oppenheimer. Firm believes the name is currently undervalued.

ORBK is up 41.27% year-over-year, compared with a 1.36% gain in the S&P 500.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.